Literature DB >> 34819620

The dawn of a new era of targeted therapies for heart failure with preserved ejection fraction (HFpEF).

Kenji Harada1, Kazuomi Kario2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34819620     DOI： 10.1038/s41440-021-00799-8

Source DB:  PubMed          Journal:  Hypertens Res        ISSN： 0916-9636            Impact factor:   3.872


× No keyword cloud information.
  2 in total

1.  Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure.

Authors:  Nikole J Byrne; Nobutoshi Matsumura; Zaid H Maayah; Mourad Ferdaoussi; Shingo Takahara; Ahmed M Darwesh; Jody L Levasseur; James Won Suk Jahng; Dyonne Vos; Nirmal Parajuli; Ayman O S El-Kadi; Branko Braam; Martin E Young; Subodh Verma; Peter E Light; Gary Sweeney; John M Seubert; Jason R B Dyck
Journal:  Circ Heart Fail       Date:  2020-01-20       Impact factor: 8.790

2.  Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis.

Authors:  Yiwen Wang; Ran Zhou; Chi Lu; Qing Chen; Tongda Xu; Dongye Li
Journal:  J Am Heart Assoc       Date:  2019-06-26       Impact factor: 5.501
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.